• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • J. P. Machiels, Richard Reilly, +5 authors Elizabeth M. Jaffee
  • Medicine
  • Cancer research
  • 2001
  • Tumor-specific immune tolerance limits the effectiveness of cancer vaccines. In addition, tumor vaccines alone have a limited potential for the treatment of measurable tumor burdens. This highlightsContinue Reading
  • Joël Guigay, Jérôme Fayette, +10 authors Jean Bourhis
  • Medicine
  • Annals of oncology : official journal of the…
  • 2015 (First Publication: 1 September 2015)
  • BACKGROUND Cetuximab in combination with platinum and 5-fluorouracil is the standard of care in the first-line treatment of patients with recurrent/metastatic head and neck squamous cell carcinomaContinue Reading
  • Cristian Villanueva, Ahmad Awada, +6 authors Xavier Pivot
  • Medicine
  • European journal of cancer
  • 2011 (First Publication: 1 May 2011)
  • BACKGROUND Most patients with metastatic breast cancer (MBC) progress after chemotherapy. Cabazitaxel (XRP6258) is a new taxoid that is active in chemotherapy-resistant tumour cell lines. TheContinue Reading
  • Jean-Philippe Van Damme, Stephen P. Schmitz, +4 authors Marc Hamoir
  • Medicine
  • European journal of surgical oncology : the…
  • 2010 (First Publication: 1 July 2010)
  • OBJECTIVES The primary objectives of this study were to analyse the outcome of patients diagnosed with head and neck soft tissue sarcomas (HNSTS) and to identify relevant prognostic factors. As wellContinue Reading
  • Ilse Van Vlaenderen, Jean Luc Canon, +7 authors Lieven Annemans
  • Medicine
  • Acta clinica Belgica
  • 2009 (First Publication: 1 April 2009)
  • Abstract Trastuzumab (Herceptin®, Roche) is a recombinant, humanized monoclonal antibody directed against the neu-HER2 protein, since May 2002 reimbursed in Belgium for the treatment of metastaticContinue Reading